|Benefit-Cost Summary Statistics Per Participant|
|Taxpayers||$1,211||Benefits minus costs||$5,982|
|Participants||$2,178||Benefit to cost ratio||n/a|
|Others||$318||Chance the program will produce|
|Indirect||$2,275||benefits greater than the costs||56 %|
|Net program cost||$0|
|Benefits minus cost||$5,982|
|Meta-Analysis of Program Effects|
|Outcomes measured||Treatment age||No. of effect sizes||Treatment N||Adjusted effect sizes(ES) and standard errors(SE) used in the benefit - cost analysis||Unadjusted effect size (random effects model)|
|First time ES is estimated||Second time ES is estimated|
Alcohol use disorder
Clinical diagnosis of alcohol use disorder or symptoms measured on a validated scale.
Illicit drug use disorder
Clinical diagnosis of illicit drug use disorder or symptoms measured on a validated scale. When possible, we exclude cannabis/marijuana use disorder from this outcome.
Opioid use disorder^^
Clinical diagnosis of opioid use disorder or symptoms on a validated scale.
Cannabis use disorder
Clinical diagnosis of cannabis use disorder or symptoms measured on a validated scale.
|Detailed Monetary Benefit Estimates Per Participant|
|Affected outcome:||Resulting benefits:1||Benefits accrue to:|
|Alcohol use disorder||Criminal justice system||$0||$0||$1||$0||$1|
|Labor market earnings associated with alcohol abuse or dependence||$823||$1,932||$0||$0||$2,755|
|Property loss associated with alcohol abuse or dependence||$0||$2||$5||$0||$7|
|Illicit drug use disorder||Health care associated with illicit drug abuse or dependence||$304||$47||$313||$152||$816|
|Mortality associated with illicit drugs||$84||$196||$0||$2,123||$2,403|
|Detailed Annual Cost Estimates Per Participant|
|Annual cost||Year dollars||Summary|
|Program costs||$1,050||2014||Present value of net program costs (in 2018 dollars)||$0|
|Comparison costs||$1,050||2014||Cost range (+ or -)||15 %|
Benefits Minus Costs
Benefits by Perspective
Taxpayer Benefits by Source of Value
|Benefits Minus Costs Over Time (Cumulative Discounted Dollars)|
|The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment.|
Allsop, S., Saunders, B., Phillips, M., & Carr, A. (1997). A trial of relapse prevention with severely dependent male problem drinkers. Addiction, 92, 61-74.
Bennett, G.A., Withers, J., Thomas, P.W., Higgins, D.S., Bailey, J., Parry, L., & Davies, E. (2005). A randomised trial of early warning signs relapse prevention training in the treatment of alcohol dependence. Addictive Behaviors, 30(6), 1111-1124.
Jafari, E., Eskandari, H., Sohrabi, F., Delavar, A., Heshmati, R., & World Conference on Psychology, Counselling and Guidance, WCPCG-2010. (2010). Effectiveness of coping skills training in relapse prevention and resiliency enhancement in people with substance dependency. Procedia - Social and Behavioral Sciences, 5, 1376-1380.
McKay, J.R., Alterman, A.I., Cacciola, J.S., O'Brien, C.P., Koppenhaver, J.M., & Shepard, D.S. (1999). Continuing care for cocaine dependence: Comprehensive 2-year outcomes. Journal of Consulting and Clinical Psychology, 67(3), 420-427.
O'Connell, J.M. (1987). Effectiveness of an alcohol relapse prevention program. (Doctoral dissertation, Fordham University, 1987, UMI No. 8725685).
Wells, E.A., Peterson, P.L., Gainey, R.R., Hawkins, J.D. & Catalano, R.F. (1994). Outpatient treatment for cocaine abuse: A controlled comparison of relapse prevention and twelve-step approaches. American Journal of Drug and Alcohol Abuse, 20(1), 1-17.